Plot No. 19A, 2nd floor, Sector - 16A, Noida - 201 301 Uttar Pradesh, India **T +91 120 485 5999 F +91 120 485 5902**

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

- 1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Jubilant Ingrevia Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 31 December 2024 and the consolidated year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended).
- 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended). Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

- 4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review report of the other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5. The Statement also includes the Group's share of net profit/(loss) after tax of ₹ 1 lakhs and ₹ (5) lakhs and total comprehensive income/(loss) of ₹ 1 lakhs and ₹ (5) lakhs, for the quarter and year-to-date period ended on 31 December 2024, respectively, as considered in the Statement, in respect of an associate, whose interim financial information has not been reviewed by us. This interim financial information has been reviewed by us. This interim financial information has been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor.

For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013

Madhu Sudan

Madhu Sudan Malpani Partner Membership No. 517440

UDIN: 25517440BMLKBX1468

Place: Gurugram Date: 28 January 2025



Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Annexure 1

List of entities included in the Statement:

S. No.	Name	Relationship with the Holding Company
1	Jubilant Infrastructure Limited	Subsidiary
2	Jubilant Agro Sciences Limited	Subsidiary
3	Jubilant Life Sciences (USA) Inc.	Subsidiary
4	Jubilant Life Sciences NV	Subsidiary
5	Jubilant Life Sciences International Pte. Limited	Subsidiary
6	Jubilant Life Sciences (Shanghai) Limited	Subsidiary
7	Jubilant Ingrevia Employee Welfare Trust	Subsidiary
8	Mister Veg Foods Private Limited	Associate
9	AMP Energy Green Fifteen Private Limited	Associate



Chartered Accountants

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2024

			Quarter Ended		Nine Mon	ths Ended	Year Ende
. No.	Particulars	31 December	30 September	31 December	31 December	31 December	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
_		2024	2024	2023	2024	2023	2024
1	Revenue from operations				1. U		
	a) Sales/Income from operations	104606	102900	96045	308551	304021	410
	b) Other operating income	1071	1624	595	4084	2115	3
	Total revenue from operations	105677	104524	96640	312635	306136	413
2	Other income	943	1046	878	2946	2580	3
3	Total income (1+2)	106620	105570	97518	315581	308716	412
4	Expenses						
	a) Cost of materials consumed	52541	51175	50113	156915	155272	20
	b) Purchases of stock-in-trade	903	819	1814	2462	5315	
	 c) Changes in inventories of finished goods, stock-in-trade and work-in progress 	419	(1283)	(1067)	(1944)	(4178)	
- 1	d) Employee benefits expense	10515	11270	10112	31935	29801	3
	e) Finance costs	1239	1507	1506	4173	3904	
	f) Depreciation and amortisation expense	3976	3960	3424	11824	10045	1
	g) Other expenses:						
		11408	12727	11104	35926	40357	5
- 1	- Power and fuel expense - Others	16052	17359	15007	50102	46581	
	Total expenses	97063	97534	92013	291393	287097	39
-		9557	8036	5505	291393	21619	
5	Profit before share of profit/(loss) of an associate (3-4)				-	7	
6	Share of profit/(loss) of an associate	1	(14)	1	(5)	1 1	
	Profit before tax (5+6)	9558	8022	5508	24183	21626	
8	Tax expense						
	- Current tax	2202	2549	1188	5999	4129	
	- Deferred tax charge	418			472	2133	
9	Net profit for the period/year (7-8)	6938	5900	3856	17712	15364	
10	Other comprehensive income (OCI)		*				
	a) Items that will not be reclassified to profit or loss	(175		17			
	b) income tax relating to items that will not be reclassified to profit or loss	21	66	40	86	105	
	ii) a) Items that will be reclassified to profit or loss	(602) 559	328	(100)		
	b) Income tax relating to items that will be reclassified to profit or loss	21	(177	(159)	(131)) (58)	
11	Total comprehensive income for the period/year (9+10)	6203	6051	3933	17290	15384	
	Net profit attributable to:						
	Owners of the Company	6938	5900	3856	17712	15364	
	Non-controlling interests		39	®	<u> </u>		
	Other comprehensive income attributable to:					1	
	Owners of the Company	(735) 151	77	(422) 20	
	Non-controlling interests			4			
	Total comprehensive income attributable to:						
	Dwners of the Company	6203	6051	3933	17290	15384	
	Non-controlling interests			ж.			
12	Earnings per share of ₹ 1 each (not annualised for the quarters/periods)				E.		
	Basic (₹)	4.39	3.73	2.44	11.20	9.71	
	Diluted (₹)	4.39	3.73	2.43	11.20	9.70	
13	Paid-up equity share capital (face value per share ₹ 1)	1581					
14	Reserves excluding revaluation reserves (other equity)						1 :
	See accompanying notes to the Consolidated Unaudited Financial Results			1	1	1	



SIGNED FOR



Note 1: Consolidated Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Nine Months Ended 31 December 2024

			Quarter Ended		Nine Mon	ths Ended	Year Ended
		31 December	30 September	31 December	31 December	31 December	31 March
Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	50	2024	2024	2023	2024	2023	2024
1	Segment revenue			>			
	a. Speciality Chemicals	52925	50442	40427	150900	131640	184905
	b. Nutrition & Health Solutions	18955	18240	15122	55829	51550	68011
	c. Chemical Intermediates	40084	43221	46829	124333	145654	189704
	Total	111964	111903	102378	331062	328844	442620
	Less : Inter segment revenue	6287	7379	5738	18427	22708	29040
	Total revenue from operations	105677	104524	96640	312635	306136	413580
	a. Speciality Chemicals	46764	43317	36478	133147	111027	15855
	b. Nutrition & Health Solutions	18955	18209	15122	55775	51550	6800
	c. Chemical Intermediates	39958	42998	45040	123713	143559	18702
	Total	105677	104524	96640	312635	306136	41358
2	Segment results (profit before tax and interest)						
	a. Speciality Chemicals	9782	6287	3486	22319	12303	1683
	b. Nutrition & Health Solutions	2191	2077	1409	6230	4296	486
	6. Chemical Intermediates	973	2804	3774	6131	12679	1587
	Total	12946	11168	8669	34680	29278	3757
	Less: i. Interest (finance costs)	1239	1507	1506	4173	3904	526
	ii. Un-allocable expenditure (net of un-allocable income)	2149	1639	1655	6324	3748	554
	Profit before tax	9558	8022	5508	24183	21626	2676
3	Segment assets						
	a. Speciality Chemicals	269347	259119	254251	269347	254251	26709
	b. Nutrition & Health Solutions	63863	62857	49961	63863	49961	5182
	c. Chemical Intermediates	148017	146967	133874	148017	133874	13855
	d. Unallocable corporate assets	13997	15186	12667	13997	12667	1571
	Total segment assets	495224	484129	450753	495224	450753	47318
4	Segment liabilities						
	a. Speciality Chemicals	49412	49395	28194	49412	28194	4098
	b. Nutrition & Health Solutions	8183	8660	9778	8183	9778	1233
	c. Chemical Intermediates	50848	48927	47281	50848	47281	4864
	d. Unallocable corporate liabilities	98463	95611	91321	98463	91321	9749
	Total segment liabilities	206906	202593	176574	206906	176574	19944





σ
e,
÷.
5
ia.
N
ē
Ξ.
B
Ē
_
-
2
O
0
-

Note 2: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

	(masses)		Quarter Ended		Nine Mon	Nine Months Ended	Year Ended
- N	Darticular	31 December	30 September	31 December	31 December	31 December	31 March
Sr. No.		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2024	2024	2023	2024	2023	2024
Ч	Debt service coverage ratio (in times)#	6.00	8.95	6.93	7.45	9.11	8,67
	Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-						
	term debts} Tebirn A. Booft konfore for a deareointion and amortication evenere a finance castel						
~	(contrast regired) at a vepreduction and unior useduar capense i jinance costy Interest service coverage ratio (in times)	11.92	8.95	6.93	9.63	9.11	8.67
1	Definition: EBITDA/finance costs						5
m	Bad debts to account receivable ratio (%)#	0.01%	(0.01%)	0.27%	0.01%	0.33%	0.43%
	Definition: Bad debts/average of opening and closing trade receivables						
	[Bad debts: Impairment balance as per statements of profit and loss]						40 E
4	Debtors turnover (in times)#	1.79	1.81	2,17	5.37	6.45	/ ,04
	Definition: Revenue from operations/average of opening and closing trade receivables	C		07.0	1 64	1 52	217
Ś	line trony turnover (in times)#	86.0	cc.0	0,43	1:04	70.4	
u	Uerinition: Lost of goods sola/average of opening and closing inventories Deserving mayoin (92)	%CE 0	8.13%	6.35%	8.13%	7.49%	6.89%
D	Operating margim (vo) Definition: Operating profit/revenue from operations	247:7					
	Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and						
	amortisation expense - other expenses)						
	(Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods,						
	stock-in-trade and work-in-progress}						
7	Net profit margin (%)	6.51%	5.59%	3.95%	5.61%	4.98%	4.38%
	Definition: Net profit/total income						
∞	Net worth (In ₹ Lakhs)	288318	281536	274179	288318	274179	273747
	[Net worth: Equity share capital + other equity]					1	
σ	Debt equity ratio (in times)	0.24	0.23	0.23	0.24	0.23	0.24
	Definition: Net debts/net worth						
	(Net debts: Long term borrowings (gross of transaction costs) + Short term borrowings - cash and cash equivalents -						
ç	otriet bank bulances) Ct acits (in eimos)	1 22	1 32	1 43	1.33	1.43	1.38
2	Current ratio (in urnes) 0.6 - 450-70 - 70-450-46 August Au	0 0	707	1			
5	vermuoni. current ussets/current noomues I one term debt to warkine capital (in times)	0.99	1.05	0.59	66.0	0.59	0.91
1	Definition: I non term debt/working conital						
	Actimication active						
	(working capital: Current assets - current liabilities)						+
12	Current liability ratio (in times)	0.67	0.67	0.67	0.67	0.67	0.64
}	Definition: Current liabilities/total liabilities						
13	Total debts to total assets (in times)	0.15	0.15	0.15	0.15	0.15	0.15
					(Valen)		
	[Total debts: Long term borrowings (gross of transaction costs + short term borrowings)				~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		
# not ani				B	-		
		is.	GNED	19	Nota		
	N A A	10F3	2 Out	E C	De la		
	Contraction of the second seco	Ō	UN COURT	NO)*		
	A A A A A A A A A A A A A A A A A A A		前のつして	12)		
	- AUCH	-					

Notes to consolidated unaudited financial results (cont'd):

- 3. These consolidated unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4. The Board of Directors at its meeting held on 28 January 2025 has declared an interim dividend of ₹2.5 per share of ₹1 each amounting to ₹3982 lakhs.
- As on 31 December 2024, the Holding Company has outstanding unsecured listed commercial papers (CPs) of ₹ 14800 lakhs. These CPs are listed on the National Stock Exchange of India. Details of CPs are as follows:

ISIN No.	Issue date	Due date of repayment	Redemption amount
INEOBY014334	11 December 2024	24 February 2025	₹ 10000 lakhs
INEOBY014342	27 December 2024	25 February 2025	₹ 4800 lakhs

- 6. During the quarter ended 31 December 2024, the Holding Company has granted 100291 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Holding Company.
- 7. Subsequent to the quarter ended 31 December 2024, the Holding Company has made its second tranche of its investment in O2 Renewable Energy XVIII Private Limited, a group company of O2 Power SG PTE. LTD, Singapore, a leading renewable energy developer towards establishing renewable energy power generation through solar and wind sources. It aims to access renewable energy through a captive arrangement, fulfilling the Company's power requirements and meeting its increasing demand through green energy. The Holding Company intends to complete its investment as per the milestone agreed in the Securities Subscription and Shareholders Agreement.
- 8. Previous periods figures have been regrouped/reclassified to conform to the current period classification.
- 9. The above consolidated unaudited financial results were reviewed by the Audit Committee on 27 January 2025 and approved by the Board of Directors at its meeting held on 28 January 2025. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on consolidated financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited

CEO & Managing Director

Deepak Jain

Place : Noida Date : 28 January 2025





Plot No. 19A, 2nd floor, Sector - 16A, Noida - 201 301 Uttar Pradesh, India

T +91 120 485 5999 **F** +91 120 485 5902

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

- We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Jubilant Ingrevia Limited ('the Company') for the quarter ended 31 December 2024 and the year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended).
- 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended). Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandlok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013

ANDIOK Madky Sudan Madhu Sudan Malpani Partner DACC Membership No. 517440

UDIN: 25517440BMLKBW6377

Place: Gurugram Date: 28 January 2025

Chartered Accountants

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2024

			Quarter Ended		Nine Mon	ths Ended	Year Ended
		31 December	30 September	31 December	31 December	31 December	31 March
Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2024	2024	2023	2024	2023	2024
1	Revenue from operations						
	a) Sales/Income from operations	98411	98916	91074	292855	292937	395214
	b) Other operating income	1066	1623	596	4070	2114	3511
	Total revenue from operations	99477	100539	91670	296925	295051	398725
2	Other income	2722	897	811	4541	2575	3552
3	Total income (1+2)	102199	101436	92481	301466	297626	402277
4	Expenses						
	a) Cost of materials consumed	52744	50562	50113	156338	155272	203905
	b) Purchases of stock-in-trade	903	819	1437	2462	3571	4403
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1293)	(385)	(1220)	(1799)	(3523)	668
	d) Employee benefits expense	9373	10177	9005	28712	26623	3427
	e) Finance costs	1533	1731	1846	4933	4964	662
	f) Depreciation and amortisation expense	3718	3702	3364	11053	9862	1331
	g) Other expenses:						
	- Power and fuel expense	12043	13051	11502	37127	41306	5332
	- Others	12621	13529	13433	39399	40894	5583
	Total expenses	91642	93186	89480	278225	278969	37837
5	Profit before tax (3-4)	10557	8250	3001	23241	18657	2390
6	Tax expense						
	- Current tax	2068	2002	525	5025	3219	528
	- Deferred tax charge	429	230	543	861	2291	236
7	Net profit for the period/year (5-6)	8060	6018	1933	17355	13147	1624
8	Other comprehensive income (OCI)						
	 a) items that will not be reclassified to profit or loss 	(162	(290)	(110)	(487)	(330)	(13
	b) Income tax relating to items that will not be reclassified to profit or loss	10	73	38	92	115	3
	ii) a) Items that will be reclassified to profit or loss	2	120	542	8	*	*
	b) Income tax relating to items that will be reclassified to profit or loss						
9	Total comprehensive income for the period/year (7+8)	7908	5801	1861	16960	12932	1614
10	Earnings per share of ₹ 1 each (not annualised for the quarters/periods)						
	Basic (₹)	5:06	3.78	1.21	10.90	8.25	10.2
	Diluted (₹)	5.06	3.78	1.21	10.90	8.25	10.2
11	Paid-up equity share capital (face value per share ₹ 1)	1593	1593	1593	1593	1593	159
12	Reserves excluding revaluation reserves (other equity)						22311
	See accompanying notes to the Standalone Unaudited Financial Results						





Note 1: Standalone Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Nine Months Ended 31 December 2024

			Quarter Ended		Nine Mon	ths Ended	Year Ended
		31 December	30 September	31 December	31 December	31 December	31 March
Sr. No.	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	**	2024	2024	2023	2024	2023	2024
1	Segment revenue)			
	a _ Speciality Chemicals	52631	50621	39238	148539	129418	182612
	b. Nutrition & Health Solutions	18503	18231	14273	53984	52862	67088
	c. Chemical Intermediates	34630	39066	43897	112829	135479	178065
	Total	105764	107918	97408	315352	317759	427765
	Less : Inter segment revenue	6287	7379	5738	18427	22708	29040
	Total revenue from operations	99477	100539	91670	296925	295051	398725
	a. Speciality Chemicals	46470	43496	35289	130786	108805	156261
	b. Nutrition & Health Solutions	18503	18200	14273	53930	52862	67077
	c. Chemical Intermediates	34504	38843	42108	112209	133384	175387
	Total	99477	100539	91670	296925	295051	398725
2	Segment results (profit before tax and interest)						
	a. Speciality Chemicals	10836	6564	3476	23297	12716	17586
	b. Nutrition & Health Solutions	2659	2124	977	6351	4725	5222
	ct Chemical Intermediates	656	3053	2052	4875	9927	13239
	Total	14151	11741	6505	34523	27368	36047
	Less: i. Interest (finance costs)	1533	1731	1846	4933	4964	6629
	ii. Un-allocable expenditure (net of un-allocable income)	2061	1760	1658	6349	3747	5518
	Profit before tax	10557	8250	3001	23241	18657	23900
3	Segment assets						
	a. Speciality Chemicals	236825	231676	228737	236825	228737	238512
	b. Nutrition & Health Solutions	52988	50008	37818	52988	37818	37074
	c. Chemical Intermediates	124824	121829	119540	124824	119540	122727
	d. Unallocable corporate assets	36721	36988	33214	36721	33214	35727
	Total segment assets	451358	440501	419309	451358	419309	434040
4	Segment liabilities					5	
	a. Speciality Chemicals	46760	47395	26657	46760	26657	38760
	b. Nutrition & Health Solutions	13790	14113	12627	13790	12627	13464
	c+ Chemical Intermediates	48863	46423	49047	48863	49047	49788
	d. Unallocable corporate liabilities	103364	102228	105761	103364	105761	107322
	Total segment liabilities	212777	210159	194092	212777	194092	209334





Note 2: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Sr. No.			Quarter Ended		Nine Mon	Nine Months Ended	Year Ended
37.100 33		31 December	30 September	31 December	31 December	31 December	31 March
ч с w	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
-1 V M		2024	2024	2023	2024	2023	2024
M 7	Debt service coverage ratio (in times)# Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts} {EBITDA: Profit before tax + depreciation and amortisation expense + finance costs}	5.74	7.91	4.45	6.37	6.75	6.61
сń	Interest service coverage ratio (in times)	10.31	7.91	4.45	7.95	6.75	6,61
	Definition: EBITUA/Jinance costs Bad debts to account receivable ratio (%)#	0.01%	(0.01%)	0.27%	0.01%	0.34%	0 44%
	Definition: Bad debts/average of opening and closing trade receivables Und debts: Innoirment halance as over statements of analit and loss?						
4	Debtors turnover (in times)#	1.67	1.76	2.07	5.13	6.42	7.52
	Definition: Revenue from operations/average of opening and closing trade receivables		:				ſ
ഹ	Inventory turnover (in times)# Definition: Port of acode cold/merica of menion and closing inventories	0.70	0.69	75.0	7.99	T./8	7.00
9	bejimment. cost of govers sound user age of operiming and crosing inventories Operating margin (%)	9.42%	9.04%	4.40%	7.96%	7.13%	6.77%
	Definition: Operating profit/revenue from operations {Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense						-1
	- otner expenses) {Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in- trade and work-in-proaress}						
7	Net profit margin (%) Definition: Net profit/total income	7.89%	5.93%	2.09%	5.76%	4.42%	4.04%
∞	// Net worth (In ₹ Lakhs)	238582	230342	225217	238582	225217	224706
	{Net worth: Equity share capital + other equity}						
6	Debt equity ratio (in times) Definition: Net Aphte /net worth	0.33	0.34	0.37	0.33	0.37	0.36
	beginned. Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank [balances]						
10	Current ratio (in times)	1.21	1.16	1.11	1.21	1.11	1.11
ţ	Definition: Current assets/current liabilities	, 0	07 0	010	1 8 1	7 19	17 0
1	Long term dept to working capital (in tumes) Definition: Lona term debt/working capital	TOT	24.7	67.7	10.1	1.1	Ì
	{Long term debt: Long term borrowings (gross of transaction costs}						
ç	{working capital: Current assets - current liabilities}			85.0	0 51	0.68	0.66
17	Current Hability ratio (in times) Definition: Current Inhilities Antral Hinhilities	0.04	0.03	0.0	0.04	2	
13	Total debts to total assets (in times)	0.18	0.18	0.20	0.18	0.20	0.19
	Definition: Total debts/total assets Total debts: Jonn term barrowings (prose of transaction costs) + shart term barrowings)				(
				10.7	Now X		
¢ not ani	# not annualised for the quarters/periods	SIGNED	C FOR	JUBIO	Limite		
	REPERTING	da lo	NOVINGS	m	De la		

44

Notes to standalone unaudited financial results (cont'd):

- 3. These standalone unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4. The Board of Directors at its meeting held on 28 January 2025 has declared an interim dividend of ₹2.5 per share of ₹ 1 each amounting to ₹ 3982 lakhs.
- 5. As on 31 December 2024, the Holding Company has outstanding unsecured listed commercial papers (CPs) of ₹ 14800 lakhs. These CPs are listed on the National Stock Exchange of India. Details of CPs are as follows:

ISIN No.	Issue date	Due date of repayment	Redemption amount
INEOBY014334	11 December 2024	24 February 2025	₹ 10000 lakhs
INE0BY014342	27 December 2024	25 February 2025	₹ 4800 lakhs

- 6. During the quarter ended 31 December 2024, the Company has granted 100291 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Company.
- 7. Subsequent to the quarter ended 31 December 2024, the Company has made second tranche of its investment in O2 Renewable Energy XVIII Private Limited, a group company of O2 Power SG PTE. LTD, Singapore, a leading renewable energy developer towards establishing renewable energy power generation through solar and wind sources. It aims to access renewable energy through a captive arrangement, fulfilling the Company's power requirements and meeting its increasing demand through green energy. The Company intends to complete its investment as per the milestone agreed in the Securities Subscription and Shareholders Agreement.
- 8. Previous periods figures have been regrouped/reclassified to conform to the current period classification.
- 9. The above standalone unaudited financial results were reviewed by the Audit Committee on 27 January 2025 and approved by the Board of Directors at its meeting held on 28 January 2025. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on standalone financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited

Deepak Jain

CEO & Managing Director

Place : Noida Date : 28 January 2025





QUARTERLY INTEGRATED FILING (FINANCIAL)

B. <u>STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE,</u> <u>QUALIFIED INSTITUTIONS PLACEMENT ETC.</u>

Statement on deviation / variation in utilisation	of funds raised
Name of listed entity	Jubilant Ingrevia Limited
Mode of Fund Raising	NA
Date of Raising Funds	NIL
Amount Raised	NIL
Report filed for Quarter ended	NIL
Monitoring Agency	not applicable
Monitoring Agency Name, if applicable	NIL
Is there a Deviation / Variation in use of funds raised	NA

NIL					
NIL					
NA					
Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
NA	NA	NA	NA	NA	NA
	NIL NIL NIL NIL NA Modified Object, if any	NIL NIL NIL NIL NA Modified Object, if any Original Allocation	NIL NIL NIL NIL NIL NA Modified Object, if any Original Allocation, if any	NIL NIL NIL NIL NIL NA Modified Object, if any Allocation if any If any	NIL NIL NIL NIL NIL NIL NA Modified Object, if any Original Allocation, if any If any Funds Amount of Deviation/Variation for the quarter according to applicable object

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

S. No.	Particulars	in INR crore
1.	Loans / revolving facilities like cash credit from banks / financial institutions	
А	Total amount outstanding as on date	748
В	Of the total amount outstanding, amount of default as on date	0
2.	Unlisted debt securities i.e. NCDs and NCRPS	
А	Total amount outstanding as on date	0
В	Of the total amount outstanding, amount of default as on date	0
3.	Total financial indebtedness of the listed entity including short-term	748
	and long-term debt	